Rotigotine Application Scope

Rotigotine is indicated for the management of Parkinson’s disease, including early and advanced stages, to help improve motor function and reduce symptoms such as tremor, rigidity, and bradykinesia. It is also approved for the treatment of moderate to severe Restless Legs Syndrome (RLS) in adults, providing relief from uncomfortable sensations in the legs and the strong urge to move them, particularly during periods of rest or at night.

Rotigotine Characteristics

Ingredients: Rotigotine
Properties: Dopamine agonist; non-ergot derivative; transdermal delivery system
Packaging Specification: 28 mg × 1 vial/box
Storage: Store at room temperature; keep patches in original pouch until use; protect from heat and moisture
Expiry Date: As indicated on packaging (typically 24–36 months from manufacturing date)
Executive Standard: In accordance with the pharmacopoeia and regulatory requirements
Approval Number: As per the national drug regulatory authority
Date of Revision: Latest update per product labeling
Manufacturer: As per product packaging

Guidelines for the Use of Jinyouping

Dosage and Administration:
- Recommended Dose:
  - Parkinson’s disease: starting dose usually 2 mg/24 h, titrated to optimal clinical effect (up to 16 mg/24 h)
  - Restless Legs Syndrome: starting dose 1 mg/24 h, may be increased to 3 mg/24 h
- Administration: Transdermal patch; change patch every 24 hours
- Missed Dose: Apply a new patch as soon as remembered; do not apply two patches at once
Adverse Reactions:
- Common Adverse Reactions: Nausea, vomiting, dizziness, headache, somnolence, insomnia, peripheral edema, application site reactions
- Serious Adverse Reactions: Impulse control disorders (e.g., compulsive gambling, hypersexuality), hallucinations, orthostatic hypotension, sudden sleep episodes, severe skin reactions
Contraindications:
- Known hypersensitivity to rotigotine or patch excipients
- Severe allergic reactions to adhesives
- Conditions where dopamine agonists are contraindicated
Precautions:
- Monitor for sudden sleep onset, psychiatric symptoms, or behavioral changes.
- Use with caution in patients with cardiovascular disease, hypotension, or a history of psychosis.
- Gradual dose reduction is recommended when discontinuing to avoid withdrawal symptoms.

Rotigotine Interactions

May interact with dopamine antagonists (e.g., antipsychotics, metoclopramide) → reduced efficacy.
Caution with concomitant sedatives or alcohol → additive sedative effects
May enhance hypotensive effects when combined with antihypertensive drugs

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.